Thyrocare Technologies Limited (hereinafter referred to as THYROCARE NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, has announced its financial results for the first quarter ...

Thyrocare Technologies Limited reported a robust 23% year-on-year revenue growth in Q1FY26. The company's core Pathology segment significantly contributed to this surge.

Dr. A Velumani, Thyrocare's founder, advises parents against overindulging their children, emphasizing the crucial roles of ...

What struck him most was Redcliffe Labs’ pace. “Had an hour of interaction on how it is going for @Redcliffe Labs. I hear a growth in 3 years a turnover that I took 15 years to reach,” he wrote.

Thyrocare founder Dr. A Velumani sparks debate with his viral video criticizing the over-scheduling of city children. He ...

Thyrocare Technologies shares zoomed 12.66 per cent in trade, hitting a 52-week high at ₹1,356.95 per share on the BSE.

Thyrocare’s consolidated net profit rose 59.9% to INR 38.3 Cr in Q1 FY26 from INR 23.9 Cr in the year-ago quarter ...

Franchise-led expansion has been the key driver behind Thyrocare’s strong Q1 performance, with CEO Rahul Guha attributing the 23% revenue growth and 60% profit surge to the addition of 1,500 new ...

Thyrocare Technologies has a P/E ratio of 29.82, based on the last twelve months. In other words, at today's prices, investors are paying ₹29.82 for every ₹1 in prior year profit.

While Thyrocare Technologies doesn't seem to have gained much on the EBIT line, at least earnings remain stable for now. There's no doubt that we learn most about debt from the balance sheet.

Thyrocare, the healthcare service provider in the diagnostic segment, has unveiled its new brand identity that reflects the dramatic transformation of the company over the last 25 years.

The message struck a chord with many, as it highlighted the difference between external appearances and internal contentment.